Saturday 17 October 2026
Export TRVN’s income statement to Excel — free account
Trevena, Inc.
TRVN Healthcare Biotechnology
Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.07
−100.00%
Follow TRVN
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | — | 1 |
| (1,014.58%) | 1,784.36% | 807.12% | 344.49% | ||
| (90.25%) | (115.65%) | (119.82%) | (105.83%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(139.67%) | (201.97%) | (267.48%) | (355.58%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(64.93) | (37.06) | (36.96) | (31.76) | |
Free Cash Flow |
(33.08) | (31.58) | (31.51) | (27.09) | |
Capital Expenditures |
(0.04) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(58.93%) | (71.18%) | (108.91%) | (116.23%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.71 | 0.82 | 0.90 | 1.29 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
503.35 | 520.76 | 251.02 | 211.40 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
522.66% | 522.11% | 3,504.51% | 2,404.95% | |
Selling, General and Administrative Expense of Revenue |
653.12% | 642.43% | 4,204.51% | 3,284.62% | |
Share Based Compensation of Revenue |
93.76% | 89.36% | 607.45% | 468.50% | |
Interest Coverage |
(9.68) | (9.44) | (11.37) | (11.07) | |
Operating CF/Net income |
0.82 | 0.79 | 0.85 | 0.80 | |
Depreciation/Fixed assets |
0.28 | 0.31 | 0.34 | 0.39 | |
Capex/Depreciation |
(0.12) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
6.13 | 3.68 | 0.52 | 0.64 | |
Operating CF per Share |
(64.85) | (37.06) | (36.96) | (31.76) | |
Capex per Share |
(0.08) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 |
Columns are period end dates